Project Details
Description
DESCRIPTION (provided by applicant): Varicella zoster virus (VZV) is a
ubiquitous human herpesvirus and is the infectious agent of chickenpox
(varicella) and shingles (zoster). Both varicella and, particularly, zoster
continue to be health problems. A vaccine is in widespread use in children and
may be used in the future in older adults, but we still do not know much about
the pathogenesis of VZV infections (e.g. we do not understand the basis for
attenuation of the vaccine virus). The study of VZV has been hampered by its
human host range and its poor growth in cell culture. During the last granting
period, we formed a consortium to develop a SCIDhu mouse model for the study of
VZV pathogenesis in human fetal skin and thymus/liver implants. In this model,
the pathology of infections appears authentic, the virus produced resembles
that from actual human lesions and the vaccine virus is attenuated. We produced
a series of VZV mutants and discovered several virulence determinants for the
virus. In this proposal we will capitalize on our success with this model and
extend it to allow study of human neural tissues. We will also study, in
detail, two viral proteins - IE62 and the ORF47 protein kinase; the first of
these is a (the) major viral gene regulatory protein and the second an
indispensable (in SCIDhus) viral protein. Both in vitro and in vivo approaches
will be taken and we will generate a new series of VZV mutants. In a new final
aim, we will explore the structure of VZV particles, using the authentic
material derived from SCIDhu growth. Understanding VZV pathogenesis will be the
guide to designing "second generation" VZV vaccines.
| Status | Finished |
|---|---|
| Effective start/end date | 09/25/01 → 09/24/03 |
Funding
- National Institute of Allergy & Infectious Disease: $148,764.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.